Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities
KALYDECOTM (ivacaftor) is currently approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the CFTR gene (approximately 2,000 people with CF worldwide). In 2013 … Enacted as part of the 2012 Food and Drug …
Read more on DailyFinance

Alnylam Provides Key 2013 – 2014 Goals for RNAi Therapeutics Pipeline
"In 2012, we made tremendous progress in our RNAi therapeutic development efforts with our 'Alnylam 5×15' product strategy focused on genetically defined targets for diseases with limited treatment options for patients and their caregivers. … There …
Read more on MarketWatch (press release)

Efforts to stop sex trafficking continue despite lack of statistics
Those factors include threats of harm, intimidation, bullying, blackmail and coerced or forced drug use to the point of addiction and dependence, Benitez said. Homeless and … Nationwide, task forces funded through the Trafficking Victims Protection …
Read more on The Advocate